2026-01-04 - Analysis Report
Okay, let's break down the provided information on Tempus AI Inc. (TEM).

**1. Return Analysis**

*   **Simple Numbers:**
    *   TEM Cumulative Return: 10.82%
    *   S&P 500 (VOO) Cumulative Return: 28.20%
    *   Divergence (TEM - VOO): -23.10%
    *   Relative Divergence: 14.7 (Indicates it's near the low end of historical divergence.)

*   **Simple Analysis:**
    *   Tempus AI Inc is a technology company that focuses on precision medicine through data analysis.
    *   TEM has significantly underperformed the S&P 500 over the observed period. The divergence of -23.1% indicates a substantial gap in returns. The relative divergence of 14.7 suggests that this underperformance is relatively close to its worst historical levels compared to VOO.
    *   This underperformance may suggest that the company carries more risk or is in a phase where it has not yet achieved its growth potential relative to the broader market.

*   **Alpha, Beta Analysis:**
    *   CAGR (2024-2026): 11.0%
    *   MDD (2024-2026): 56.3%
    *   Alpha (2024-2026): -16.0%
    *   Beta (2024-2026): 2.8
    *   Cap(B): 11.1

    *   **Analysis:**
        *   The projected CAGR of 11.0% is optimistic but comes with a very high Maximum Drawdown (MDD) of 56.3%, indicating substantial potential for loss.
        *   The negative Alpha of -16.0% suggests that TEM is underperforming relative to what its Beta would predict. This means it is not generating excess returns compared to its risk profile.
        *   The Beta of 2.8 means TEM is significantly more volatile than the market (S&P 500), amplifying both gains and losses. TEM is 2.8 times more volatile than the market.
        *   Cap(B) means market capitalization in billions

**2. Recent Stock Price Fluctuations**

*   **Simple Numbers:**
    *   Current Close: 62.36
    *   Previous Close: 59.05
    *   Change: +5.61
    *   5-day SMA: 61.194
    *   20-day SMA: 67.7193
    *   60-day SMA: 76.896

*   **Simple Analysis:**
    *   The stock price recently increased (+5.61).
    *   The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This *could* indicate a short-term upward trend, but it's still below longer-term averages, implying overall downward momentum in the recent past.

**3. Indicator Analysis**

*   **Simple Numbers:**
    *   MRI: 0.8 (Medium Investment Recommended)
    *   RSI: 27.49 (Oversold)
    *   PPO: -0.72
    *   Recent (20 days) relative divergence change: -7.4 (Decreasing)
    *   Hybrid Signal: cash_0%_Buy 100% of cash
    *   Expected Return (%): NaN

*   **Simple Analysis:**
    *   The MRI of 0.8 suggests a "Medium Investment" recommendation, but this should be considered along with other indicators.
    *   The RSI of 27.49 indicates the stock is oversold, which *could* mean it is due for a rebound. However, it can also stay oversold for extended periods during a strong downtrend.
    *   The PPO of -0.72 indicates that the short-term moving average is below the long-term moving average, confirming the overall downward trend.
    *   Recent relative divergence change of -7.4 indicates short-term decline compared to the comparison index.
    *   The "Hybrid Signal" is aggressively bullish, recommending to buy 100% of available cash and invest 5% monthly, which may not be aligned to the other factors.
    *   The "Expected Return" is NaN, suggesting the model cannot predict a return at this time.

**4. Recent News & Significant Events**

*   **Analysis:** The news headlines paint a mixed picture:
    *   Some articles highlight the potential for gains in MedTech driven by AI (positive).
    *   Others indicate lowered price targets from analysts (negative).
    *   One article mentions the stock fell 8% in a week (negative).
    *   There is discussion of a "pivotal transition" (uncertain â€“ could be positive or negative).
    *   BofA and JPMorgan Lower Tempus AI, Inc. (TEM) Price Targets on Valuation Concerns

**4-2. Analyst Opinions**

*   **Simple Numbers:**
    *   Consensus: Buy (~2.14 on a scale of 1 to 5)
    *   Number of Opinions: 12
    *   Target Price: Avg 88.92 / High 105.00 / Low 80.00

*   **Analysis:**
    *   Despite recent negative news, the analyst consensus is still a "Buy" with a target price considerably higher than the current price. This suggests that analysts see potential for future growth.
    *   However, the lowered price targets referenced in the news, combined with the negative performance relative to the S&P 500, should raise concerns.
    *   The provided data does not give specifics on the three recent rating changes. It would be useful to know if they were upgrades or downgrades.

**5. Comprehensive Analysis**

Tempus AI Inc. (TEM) presents a mixed picture. While the company operates in a promising sector (AI-driven precision medicine), the stock has significantly underperformed the broader market.  The projected CAGR is appealing, but the very high MDD and negative Alpha raise serious concerns about risk and value generation.

The recent stock price decline, combined with lowered analyst price targets (BofA, JPMorgan), suggests increasing market skepticism. While the RSI indicates the stock may be oversold, this doesn't guarantee a rebound.

The analyst consensus remains a "Buy," which contrasts with the negative price movement and other indicators. It's possible analysts are taking a longer-term view, but potential investors should carefully consider the risks before investing.

**In Summary:**

*   **Risky Investment:** TEM appears to be a high-risk, high-reward investment.
*   **Contradictory Signals:** The indicators and news offer conflicting signals.
*   **Due Diligence Required:** Further investigation is warranted before making any investment decisions. Pay close attention to future news and analyst reports. Consider the recent price target reductions and the company's ability to achieve its projected growth in light of the challenges it faces. Understand the reasons for the high beta and negative alpha.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.